KLRS

Kalaris Therapeutics Inc NASDAQ Listed Jul 30, 2020

Healthcare ·Biotechnology ·US · kalaristx.com

$5.12

Pre-mkt $5.01 +4.53%

Mkt Cap $95.7M

52w Low $2.14 30.5% of range 52w High $11.88

50d MA $7.12 200d MA $6.38

P/E (TTM) -1.9x

EV/EBITDA -0.7x

P/B 1.1x

Debt/Equity 0.0x

ROE -55.1%

P/FCF -3.0x

RSI (14) —

ATR (14) —

Beta 0.18

50d MA $7.12

200d MA $6.38

Avg Volume 67.4K

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

SIC Code

2836

CIK (SEC)

1754068

Phone

+1 610 550 4220

139 Main Street, Suite 500 · Cambridge, MA 02142 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 17, 2026	AMC	-0.56	-0.44	+21.4%	8.52	-0.2%	-11.6%	-9.6%	-3.5%	-1.1%	-4.6%	—
Nov 12, 2025	AMC	-0.66	-0.64	+3.0%	4.96	-1.8%	+7.5%	+2.4%	-0.7%	+19.0%	+3.6%	—
Aug 13, 2025	AMC	-0.51	-0.61	-19.6%	2.28	+0.0%	-0.4%	+8.4%	+1.6%	+2.8%	+0.0%	—
May 14, 2025	AMC	-0.78	-2.52	-223.1%	3.38	-4.7%	+4.7%	-1.7%	-6.6%	+2.5%	-10.5%	—
Mar 7, 2025	AMC	-2.76	-3.64	-31.8%	9.87	-1.8%	-6.8%	+3.2%	+1.9%	-5.7%	+5.8%	—
Nov 12, 2024	AMC	-0.14	-0.04	+71.4%	286.45	-0.3%	+4.0%	-1.8%	+2.9%	+1.8%	-3.4%	—
Jun 30, 2024	AMC	-2.37	-1.13	+52.2%	—	—	—	—	—	—	—	—
Mar 31, 2024	AMC	-3.62	-0.68	+81.1%	—	—	—	—	—	—	—	—
Dec 31, 2023	AMC	-9.84	-0.70	+92.9%	—	—	—	—	—	—	—	—
Sep 30, 2023	AMC	—	-8.94	—	—	—	—	—	—	—	—	—
Jun 30, 2023	AMC	—	-11.00	—	1798.60	-0.3%	-4.7%	-1.5%	-3.8%	+4.6%	+1.6%	—
Mar 31, 2023	AMC	—	-10.15	—	2084.26	-0.3%	-1.0%	-2.6%	-3.2%	+3.3%	-0.8%	—

Data updated apr 25, 2026 5:36pm · Source: massive.com